Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way
This article was originally published in The Pink Sheet Daily
Pre-commercial collaborations and R&D network expansions fall in the cross hairs of IP lawyers, who look to protect everything they can as intellectual property. But with big pharma desperate to speed up drug development and conserve resources, it's likely the R&D heads have the upper hand, at least for now.
You may also be interested in...
Sanofi-Aventis Enters First R&D Pact In India For Glenmark's Pain Drugs; Instills Optimism In India's R&D Capabilities
MUMBAI - An extensive worldwide search for novel agents to treat chronic neuropathic pain has brought together Sanofi-Aventis and Indian drug maker Glenmark Pharma through a development and commercialization deal for transient receptor potential vanilloid (TRPV3) antagonist molecules
Pfizer, Lilly And Merck Strike Up Cancer Research Partnership In Asia
Eli Lilly, Pfizer and Merck - like many Big Pharma - are hoping to spur growth in the future by addressing unmet medical need in Asia's emerging markets. The three companies hope to accelerate research in addressing Asia's most-commonly diagnosed cancers with a non-competitive collaboration - perhaps the first of its kind in the region - to share data for the next several years
Pfizer, Strides Arcolab Join Forces To Manufacture And Market Oncology Injectables In U.S.
MUMBAI - After partnering with Aurobindo Pharma and Claris to source more than 100 oral and injectable generic drugs last year, Pfizer continues its shopping spree in India as it sealed yet another sourcing deal, this time with Bangalore-based Strides Arcolab